UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

International Myeloma Working Group recommendations for global myeloma care

Leukemia, 2014-05, Vol.28 (5), p.981-992

2014

Volltextzugriff (PDF)

Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma

Oral diseases, 2009-04, Vol.15 (3), p.206-213

2009

Volltextzugriff (PDF)

Therapy-related leukemia and myelodysplasia: susceptibility and incidence

Haematologica (Roma), 2007-10, Vol.92 (10), p.1389-1398

2007

Volltextzugriff (PDF)

Early hydrocephalus in Listeria meningitis: Case report and review of the literature

IDCases, 2018-01, Vol.14, p.e00455-e00455, Article e00455

2018

Volltextzugriff (PDF)

Morel Lavallée Lesion – A case report and review of literature

International journal of surgery case reports, 2020-01, Vol.76, p.103-106

2020

Volltextzugriff (PDF)

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

Leukemia, 2008-04, Vol.22 (4), p.842-849

2008

Volltextzugriff (PDF)

Image-guided core-needle biopsy in malignant lymphoma: experience with 100 patients that suggests the technique is reliable

Journal of clinical oncology, 1996-09, Vol.14 (9), p.2431-2434

1996

Volltextzugriff (PDF)

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression

Blood cancer journal (New York), 2014-08, Vol.4 (8), p.e236-e236

2014

Volltextzugriff (PDF)

AUTOIMMUNE DISEASE (AID) IS BOTH A RISK FACTOR AND A PROGNOSTIC FACTOR AFFECTING SURVIVAL IN PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL)

Hematological oncology, 2017-06, Vol.35 (S2), p.177-178

2017

Volltextzugriff (PDF)

Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

Leukemia, 2011-10, Vol.25 (10), p.1627-1631

2011

Volltextzugriff (PDF)

Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study

Leukemia research, 2017-04, Vol.55, p.S67-S68

2017

Volltextzugriff (PDF)

bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA

Molecular and Cellular Biology, 1997-03, Vol.17 (3), p.1490-1502

1997

Volltextzugriff (PDF)

Differential regulation of the apoptotic machinery during megakaryocyte differentiation and platelet production by inhibitor of apoptosis protein Livin

Cell death & disease, 2013-11, Vol.4 (11), p.e937-e937

2013

Volltextzugriff (PDF)

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL

HemaSphere, 2022-04, Vol.6 (Suppl), p.13-13

2022

Volltextzugriff (PDF)

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

2016

Volltextzugriff (PDF)

Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients

Leukemia, 2005-11, Vol.19 (11), p.1919-1928

2005

Volltextzugriff (PDF)

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-10, Vol.375 (14), p.1319-1331

2016

Volltextzugriff (PDF)

PF602 OUTCOME OF EXTRA‐MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

HemaSphere, 2019-06, Vol.3 (S1), p.254-255

2019

Volltextzugriff (PDF)

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

The New England journal of medicine, 2015-01, Vol.372 (2), p.142-152

2015

Volltextzugriff (PDF)

Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

European journal of haematology, 2018-05, Vol.100 (5), p.494-501

2018

Volltextzugriff (PDF)

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

Journal of clinical oncology, 2023-03, Vol.41 (8), p.1590-1599

2023

Volltextzugriff (PDF)

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

The lancet oncology, 2016-02, Vol.17 (2), p.200-211

2016

Volltextzugriff (PDF)

9200 ORAL A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM)

European journal of cancer (1990), 2011, Vol.47, p.S639-S639

2011

Volltextzugriff (PDF)

CT-guided Biopsy with Cutting-edge Needle for the Diagnosis of Malignant Lymphoma: Experience of 267 Biopsies

Clinical radiology, 2003-02, Vol.58 (2), p.143-147

2003

Volltextzugriff (PDF)

1 – 25 von 454

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(418)
Mit Volltextzugriff
(397)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(450)
Hebräisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(307)
Life Sciences & Biomedicine
(261)
Humans
(214)
Female
(133)
Male
(132)
Middle Aged
(111)
Biological And Medical Sciences
(103)
Medical Sciences
(93)
Aged
(85)
Adult
(78)
Cardiovascular System & Cardiology
(71)
Cardiac & Cardiovascular Systems
(69)
Hematology
(50)
Cardiovascular
(46)
Oncology
(45)
Hematologic And Hematopoietic Diseases
(38)
Treatment Outcome
(37)
Patients
(36)
Risk Factors
(36)
Physical Sciences
(34)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

International Myeloma Working Group recommendations for global myeloma care

Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma

Therapy-related leukemia and myelodysplasia: susceptibility and incidence

Early hydrocephalus in Listeria meningitis: Case report and review of the literature

Morel Lavallée Lesion – A case report and review of literature

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

Image-guided core-needle biopsy in malignant lymphoma: experience with 100 patients that suggests the technique is reliable

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression

AUTOIMMUNE DISEASE (AID) IS BOTH A RISK FACTOR AND A PROGNOSTIC FACTOR AFFECTING SURVIVAL IN PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL)

Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy

Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study

bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA

Differential regulation of the apoptotic machinery during megakaryocyte differentiation and platelet production by inhibitor of apoptosis protein Livin

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

PF602 OUTCOME OF EXTRA‐MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

9200 ORAL A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM)

CT-guided Biopsy with Cutting-edge Needle for the Diagnosis of Malignant Lymphoma: Experience of 267 Biopsies

Suchergebnisse filtern